RxDoctor Payments Data

Amy Woods, MD

Internal Medicine · Byhalia, MSNPI 1376754077

Payments from drug & device makers

$638in general payments, 2019–2025

Across 36 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$102
  • Amgen$80
  • Boston Scientific$69
  • Novo Nordisk$67
  • AbbVie$65
  • Dexcom, Inc.$45
  • plus $209 from 8 others

What the payments were for

  • Food & beverage$638100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$638 in reported general payments places this provider in the 55th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$493,011
Medicare patients
762
Services billed
13,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide91$94,039
TrulicityDulaglutide63$83,719
OzempicSemaglutide52$59,774
XareltoRivaroxaban25$32,860
EliquisApixaban23$25,926
JardianceEmpagliflozin30$25,704
JanuviaSitagliptin Phosphate23$24,651
MyrbetriqMirabegron17$20,130
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$17,165
TradjentaLinagliptin16$12,232
Breo ElliptaFluticasone/Vilanterol12$9,206
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$5,039
SynthroidLevothyroxine Sodium47$4,621
Ezetimibe127$3,626
SymbicortBudesonide/Formoterol Fumarate11$3,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$67$59,77452 claims
GSKTrelegy Ellipta, Breo Ellipta$42$26,37125 claims
PfizerEliquis$102$25,92623 claims
Astellas Pharma US IncMyrbetriq$43$20,13017 claims
AbbVieSynthroid$65$4,62147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Byhalia

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →